Last reviewed · How we verify

Kunming Baker Norton Pharmaceutical Sales Co., Ltd. — Portfolio Competitive Intelligence Brief

Kunming Baker Norton Pharmaceutical Sales Co., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DICL-SR DICL-SR marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2 Rheumatology / Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Depomed · 1 shared drug class
  2. Dong-A ST Co., Ltd. · 1 shared drug class
  3. Handok Inc. · 1 shared drug class
  4. Imprimis Pharmaceuticals, Inc. · 1 shared drug class
  5. LEO Pharma · 1 shared drug class
  6. Novartis · 1 shared drug class
  7. Pfizer · 1 shared drug class
  8. University of South Alabama · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kunming Baker Norton Pharmaceutical Sales Co., Ltd.:

Cite this brief

Drug Landscape (2026). Kunming Baker Norton Pharmaceutical Sales Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kunming-baker-norton-pharmaceutical-sales-co-ltd. Accessed 2026-05-18.

Related